One study [44] utilising CDK4/6 inhibitor on ER+/HER2− breast cancer patients and another study [118] utilising kinase inhibitor on ER+/HER2+ patients showed pCR rate of 5% (n=1) and 0% (n=1), respectively. This evidence concerns the gene ERBB2 and breast carcinoma.